natgillin/translations-raw huggingface dataset:
How is Luxturna used?
Kako se zdravilo Luxturna uporablja?
How does Luxturna work?
Kako zdravilo Luxturna deluje?
OTHER SPECIAL WARNING(S):
DRUGA POSEBNA OPOZORILA:
See situations in which this product should never be used in section 2.
Glejte v poglavju 2, v katerih primerih se to zdravilo ne sme nikoli uporabljati.
The product information may be subsequently updated by the Member State competent authorities, in liaison with the Reference Member State, as appropriate, in accordance with the procedures laid down in Chapter 4 of Title III of Directive 2001/83/EC.
Informacije o zdravilu lahko pristojni organi države članice v sodelovanju z referenčno državo članico naknadno dopolnijo, kot je primerno, po postopkih iz Poglavja 4 Naslova III Direktive 2001/83/ES.
[This statement below should be strongly emphasised (e.g. capitalized, bold letters or use of colours), the visual details of the warning on the outer and immediate packaging should be agreed with NCAs and be subject to a user test taking into account the "Guideline on the Readability of the labelling and package leaflet on medicinal products for human use" within 1 month from the Commission Decision.]
[Spodnje besedilo je treba močno poudariti (npr. velike tiskane črke, krepko poudarjene črke ali uporaba barv), vizualne podrobnosti opozorila na zunanji in primarni ovojnini morajo biti dogovorjene z nacionalnimi pristojnimi organi in biti predmet preverjanja berljivosti, ob upoštevanju smernice "Guideline on the Readability of the labelling and package leaflet on medicinal products for human use", v 1 mesecu od sklepa Komisije.]
These amendments to the relevant sections of the Summary of Product Characteristics and package leaflet are the outcome of the referral procedure.
Spremembe zadevnih poglavij povzetka glavnih značilnosti zdravila in navodila za uporabo so rezultat napotitvenega postopka.
MAHs of HES solution for infusion should amend the product information (insertion, replacement or deletion of the text, as appropriate) to reflect the wording as provided below, and in conjunction to the Scientific conclusions:
Imetniki dovoljenj za promet z zdravili, ki vsebujejo hidroksietilškrob (HES) v raztopini za infundiranje, morajo spremeniti informacije o zdravilu (vstaviti, zamenjati ali izbrisati besedilo, kot je primerno), tako da bodo odražale besedilo, ki je navedeno spodaj, in v povezavi z znanstvenimi ugotovitvami:
SEE ALL CONTRAINDICATIONS IN THE SMPC.
ZA VSE KONTRAINDIKACIJE GLEJTE POVZETEK
DO NOT USE IN SEPSIS, RENAL IMPAIRMENT, OR CRITICALLY ILL PATIENTS.
NE UPORABLJAJTE PRI SEPSI, OKVARI LEDVIC ALI KRITIČNO BOLNIH BOLNIKIH.
Warning Do not use in sepsis (severe generalised infection), renal impairment, or critically ill patients.
Opozorilo Ne uporabljajte pri sepsi (huda splošna okužba), ledvični okvari ali kritično bolnih bolnikih.
SUMMARY OF PRODUCT CHARACTERISTICS [This statement below should be added in a black box at the top of the SmPC.]
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA [Spodnje besedilo je treba dodati v črnem okvirju na vrhu povzetka glavnih značilnosti zdravila.]
Contraindications Do not use in sepsis, renal impairment, or critically ill patients.
Kontraindikacije Ne uporabljajte pri sepsi, okvari ledvic ali kritično bolnih bolnikih.
PACKAGE LEAFLET [This statement below should be added in a black box at the top of the package leaflet.]
NAVODILO ZA UPORABO [Spodnje besedilo je treba dodati v črnem okvirju na vrhu navodila za uporabo.]
Further information on Poxaconazole AHCL can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/posaconazole-ahcl.
Nadaljnje informacije za zdravilo Posaconazole AHCL so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/posaconazole-ahcl.
It is used in patients whose infection is severe or in patients with weakened immune systems, when medicines applied topically (directly on the thrush) are unlikely to work.
Uporablja se pri bolnikih s hudo okužbo ali pri tistih z oslabljenim imunskim sistemom, kadar je malo verjetno, da bi zdravila nanešena topično (neposredno na soor) učinkovala.
Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Noxafil, and do not need to be repeated for Posaconazole AHCL.
Študije o koristih in tveganjih učinkovine pri odobrenih načinih uporabe so že bile izvedene z referenčnim zdravilom Noxafil, zato jih ni treba ponoviti za zdravilo Posaconazole AHCL.
The European Medicines Agency concluded that, in accordance with EU requirements, Posaconazole AHCL has been shown to have comparable quality and to be bioequivalent to Noxafil.
Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Posaconazole AHCL primerljivo raven kakovosti in je bioekvivalentno zdravilu Noxafil.
Because Posaconazole AHCL is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker je zdravilo Posaconazole AHCL generično zdravilo in je bioekvivalentno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
Posaconazole AHCL is available as an oral suspension (40 mg/ml) which is taken with a meal or nutritional supplement.
Zdravilo Posaconazole AHCL je na voljo v obliki peroralne suspenzije (40 mg/ml), ki se jemlje z obrokom ali prehranskimi dopolnili.
Posaconazole AHCL is also used to prevent invasive fungal infections in patients whose immune system is weakened because of treatments they are receiving for blood or bone marrow cancers or medicines used in haematopoietic stem cell transplantation (a procedure where the patient's bone marrow is replaced by stem cells from a donor to form new bone marrow).
Zdravilo Posaconazole AHCL se uporablja tudi za preprečevanje invazivnih gliviih okužb pri bolnikih, katerih imunski sistem je oslabljen zaradi zdravljenja, ki ga prejemajo za rakava obolenja krvi ali kostnega mozga, ali zdravil, ki se uporabljajo pri presaditvi hematopoetskih matičnih celic (postopku, pri katerem se bolnikov kostni mozeg nadomesti z izvornimi celicami darovalca, ki tvorijo nov kostni mozeg).
Side effects reported with Posaconazole AHCL are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Posaconazole AHCL, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Posaconazole AHCL is an antifungal medicine used to treat adults with the following fungal diseases, when treatments with other antifungal medicines (amphotericin B, itraconazole or fluconazole) cannot be tolerated or have failed:
Posaconazole AHCL je protiglivično zdravilo, ki se uporablja za zdravljenje odraslih z naslednjimi glivičnimi obolenji, kadar so bila zdravljenja z drugimi protiglivičnimi zdravili (amfotericinom B, itrakonazolom ali flukonazolom) neuspešna ali jih bolnik ni mogel prenašati:
• chromoblastomycosis and mycetoma (long-term fungal infections of the skin or the tissue just below the skin, usually caused by fungal spores infecting wounds due to thorns or splinters),
• kromoblastomikoze in micetoma (dolgotrajnih glivnih okužb kože in podkožnega tkiva, ki ju navadno povzročajo glivične spore, ki okužijo rane, nastale zaradi trnov ali trsk),
For more information about using Posaconazole AHCL, see the package leaflet or contact your doctor or pharmacist.
Za več informacij o uporabi zdravila Posaconazole AHCL glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Posaconazole AHCL have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Posaconazole AHCL upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
As for every medicine, the company provided studies on the quality of Posaconazole AHCL.
Tako kot za vsako zdravilo je podjetje predložilo študije o kakovosti zdravila Posaconazole AHCL.
What measures are being taken to ensure the safe and effective use of Posaconazole AHCL?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Posaconazole AHCL?
For the treatment of fungal infections, with the exception of thrush, Posaconazole AHCL is taken at a dose of 400 mg (10 ml) twice a day, or 200 mg (5 ml) four times a day in patients who are not eating.
Pri zdravljenju glivnih okužb, razen soora, se zdravilo Posaconazole AHCL jemlje v odmerku 400 mg (10 ml) dvakrat na dan ali 200 mg (5 ml) štirikrat na dan pri bolnikih, ki ne jedo.
An overview of Posaconazole AHCL and why it is authorised in the EU
Pregled zdravila Posaconazole AHCL in zakaj je odobreno v EU
• invasive aspergillosis (fungal infection caused by Aspergillus),
• invazivne aspergiloze (glivne okužbe, ki jo povzročajo glive iz rodu Aspergillus),
This means that Posaconazole AHCL contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the EU called Noxafil.
To pomeni, da vsebuje enako učinkovino in deluje na enak način kot „referenčno zdravilo“, ki je že odobreno v EU in se imenuje Noxafil.
Posaconazole AHCL can only be obtained with a prescription and treatment should be started by a doctor who has experience in managing fungal infections or in treating patients at high risk of invasive fungal infections.
Predpisovanje in izdaja zdravila Posaconazole AHCL je le na recept, zdravljenje z njim pa mora uvesti zdravnik, ki ima izkušnje z zdravljenjem glivnih okužb ali bolnikov z visokim tveganjem za invazivne glivne okužbe.
Why is Posaconazole AHCL authorised in the EU?
Zakaj je zdravilo Posaconazole AHCL odobreno v EU?
The active substance in Posaconazole AHCL, posaconazole, is an antifungal medicine that belongs to the triazole group.
Učinkovina zdravila Posaconazole AHCL, posakonazol, je protiglivično zdravilo iz skupine triazolov.
As for all medicines, data on the use of Posaconazole AHCL are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Posaconazole AHCL stalno spremljajo.
What are the benefits and risks of Posaconazole AHCL?
Kakšne so koristi in tveganja, povezani z zdravilom Posaconazole AHCL?
Other information about Posaconazole AHCL
Druge informacije o zdravilu Posaconazole AHCL
• fusariosis (fungal infection caused by Fusarium),
• fuzarioze (glivne okužbe, ki jo povzročajo glive iz rodu Fusarium),
Posaconazole AHCL contains the active substance posaconazole and is a ‘generic medicine'.
Zdravilo Posaconazole AHCL vsebuje učinkovino posakonazol in je „generično zdravilo“.
What is Posaconazole AHCL and what is it used for?
Kaj je zdravilo Posaconazole AHCL in za kaj se uporablja?
• coccidioidomycosis (fungal infection of the lungs caused by breathing in spores).
• kokcidioidomikoze (glivne okužbe pljuč, ki jo povzroča vdihavanje spor).
Posaconazole AHCL is also used as a first-line treatment for ‘thrush', a fungal infection of the mouth and throat due to Candida.
Zdravilo Posaconazole AHCL se uporablja tudi kot zdravljenje prve izbire pri glivni okužbi ust in grla, sooru, z glivo Candido.
Therefore, the Agency's view was that, as for Noxafil, the benefit of Posaconazole AHCL outweighs the identified risk and it can be authorised for use in the EU.
Zato je menila, da koristi zdravila Posaconazole AHCL enako kot pri zdravilu Noxafil odtehtajo znana tveganja in da se zdravilo lahko odobri v EU.
The list of fungi posaconazole is active against can be found in the summary of product characteristics.
Seznam glivic, proti katerim posakonazol učinkuje, je na voljo v povzetku glavnih značilnosti zdravila.
For thrush, Posaconazole AHCL is taken as 200 mg (5 ml) on the first day followed by 100 mg (2.5 ml) once a day for the following 13 days.
Pri zdravljenju soora se zdravilo Posaconazole AHCL prvi dan vzame v odmerku 200 mg (5 ml), nato pa se 13 dni jemlje v odmerku 100 mg (2,5 ml) enkrat na dan. Za preprečevanje invazivnih glivnih okužb se zdravilo Posaconazole AHCL jemlje v odmerku 200 mg (5 ml) trikrat na dan. Trajanje zdravljenja je odvisno od bolnikovega stanja.
How has Posaconazole AHCL been studied?
Kako je bilo zdravilo Posaconazole AHCL raziskano?
How is Posaconazole AHCL used?
Kako se zdravilo Posaconazole AHCL uporablja?
How does Posaconazole AHCL work?
Kako zdravilo Posaconazole AHCL deluje?
Horse.
Konj
Treatment can be continued for a maximum of 14 consecutive days.
Zdravljenje lahko traja največ 14 zaporednih dni.
In case of doubt, it is advisable to test the urine.
V primeru dvoma je priporočljiva preiskava urina.
Approximately 70% of an orally administered dose is excreted in the urine.
Približno 70 % peroralno vnesenega odmerka se izloči z urinom.
Bioavailability after oral administration is 80-90%, but is reduced significantly if medication is administered with food.
Njegova biološka uporabnost po peroralnem dajanju je 80 do 90 % vendar pa je znatno manjša, če zdravilo dajemo ob obroku hrane.
The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Za pomožne snovi, navedene v poglavju 6.1 SPC, tabela 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo(ES) št. 470/2009.
The active substance in Quadrisol is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) No 37/2010:
Zdravilna učinkovina v Quadrisol je dovoljena učinkovina, kot je navedena v tabeli 1(dovoljene snovi) priloge Uredbe Komisije (EU) št.37/2010:
Overdosing may lead to death of treated animals.
Preveliki odmerki lahko povzročijo smrt zdravljenih živali.
INDICATION(S) Reduction of inflammation and relief of pain.
INDIKACIJA(E) Zmanjšanje vnetja in bolečine.
Both enantiomers contribute to therapeutic actions of the compound.
Oba enantiomera prispevata k terapevtskim učinkom racemata.
The terminal half-life following oral administration is 350-500 minutes and no accumulation occurs following repeated oral dosing.
Končna razpolovna doba je po peroralnem dajanju 350 do 500 minut, po večkratnem peroralnem dajanju ne prihaja do kopičenja.
Symptoms are reversible.
Simptomi so reverzibilni.
The most abundant metabolite is a monohydroxylated derivative.
Presnovek, ki nastaja v največji količini, je monohidroksilirani derivat.
Both enantiomers are equipotent PGF2α antagonists.
Oba enantiomera sta enako močna antagonista PGF2 α
Marker residue
Marker zaostanek
Steady state is reached quickly following onset of treatment.
Ravnovesno stanje doseže hitro po začetku zdravljenja.
Do not use in foals under the age of 6 months.
Ne uporabite pri žrebičkih, mlajših od 6 mesecev.
Meat and offal: 12 days
Meso in organi: 12 dni
Other NSAIDs, diuretics and substances with high protein binding may compete for binding and lead to toxic effects.
Druga nesteroidna protivnetna zdravila (NSAID), diuretiki in snovi z veliko vezavo na beljakovine lahko tekmujejo za vezna mesta, zaradi česar lahko pride do toksičnih učinkov.
130 mg For the full list of excipients, see section 6.1.
Za celoten seznam pomožnih snovi, glejte poglavje 6.1.
A 30 ml adjustable multidose syringe consisting of high density polyethylene (white) and low density polyethylene (white and natural).
Nastavljiva večodmerna brizga po 30 ml, izdelana iz polietilena visoke gostote (bele barve) in polietilena nizke gostote (bele in naravne barve).
Reduction of inflammation and relief of pain associated with musculo-skeletal disorders and soft tissue lesions (traumatic injuries and surgical trauma).
Zmanjšanje vnetja in bolečine pri mišično-skeletnih obolenjih in poškodbah mehkega tkiva (travmatskih poškodbah in kirurških travmah).
Horses intended for racing and competition should be treated according to local requirements.
Dirkalne in tekmovalne konje je treba zdraviti v skladu z nacionalnimi zahtevami.
Twice daily administration.
Zdravilo dajemo 2-krat na dan.
BATCH NUMBER Lot: {number}
ŠTEVILKA SERIJE Lot {številka}
OTHER INFORMATION For animal treatment only.
DRUGE INFORMACIJE Samo za živali.
Date of last renewal: 13 November 2007
Datum pridobitve dovoljenja za promet: 4 december 1997 Datum podaljšanja dovoljenja za promet: 13 november 2007
The (+) enantiomer is more potent in inhibiting prostaglandin synthesis.
(+) enantiomer močneje zavira sintezo prostaglandinov.
In case of prophylactic treatment, a maximum duration of treatment of 7 consecutive days is sufficient.
Pri profilaktičnem zdravljenju zadošča zdravljenje 7 zaporednih dni.
The gel is administered orally by inserting the nozzle of the syringe through the interdental space and depositing the required amount of gel on the back of the tongue.
Gel dajemo peroralno, tako da konico brizge potisnemo skozi medzobni prostor in potrebno količino gela iztisnemo na zadnjo stran jezika.
Do not use in animals suffering from alimentary tract disorders, impaired heart, liver and kidney function.
Ne uporabite pri živalih, ki imajo obolenja prebavil ali srčne, jetrne ali ledvične okvare.
Horses with oral lesions should be assessed clinically and the attending veterinarian should take a decision as to whether treatment should be continued.
Pri konjih s poškodbami v ustni votlini je treba stanje klinično oceniti, lečeči veterinar pa mora odločiti o nadaljevanju zdravljenja.
Avoid the use in any dehydrated, hypovolaemic or hypotensive animals, as there may be potential risk of increased renal toxicity.
Uporabi zdravila se je treba izogibati pri dehidriranih, hipovolemičnih ali hipotenzivnih živalih, ker se pri njih lahko poveča nevarnost toksičnih učinkov na ledvice.
MANUFACTURER'S BATCH NUMBER Lot: {number}
PROIZVAJALČEVA ŠTEVILKA SERIJE Lot {številka}
In cases of anticipated surgical trauma, Quadrisol can be given prophylactically at least 3 hours prior to elective surgery.
Če je kirurška travma pričakovana, lahko dajemo Quadrisol profilaktično najmanj 3 ure pred kirurškim posegom.
Do not use in the case of hypersensitivity to the active substance or to any of the excipients.
Ne uporabite v primeru preobčutljivosti na zdravilno učinkovino ali na katerokoli pomožno snov.
Vedaprofen is highly bound to plasma proteins and extensively metabolised.
Vedaprofen se obsežno veže na beljakovine v plazmi in v veliki količini presnavlja.
Not authorised for use in lactating animals producing milk for human consumption.
Ni dovoljena uporaba pri živalih, katerih mleko je namenjeno prehrani ljudi.
An initial dose of 2 mg/kg (2.0 ml/100 kg) is followed by a maintenance dose of 1 mg/kg (1.0 ml/100 kg) given every 12 hours.
Začetni odmerek je 2 mg/kg (2,0 ml/100 kg), nato dajemo vzdrževalni odmerek po 1 mg/kg (1,0 ml/100 kg) vsakih 12 ur.
Vedaprofen is a non-steroidal anti-inflammatory drug (NSAID) belonging to the propionic acid derivate group.
Vedaprofen je nesteroidno protivnetno zdravilo (NSAID) iz skupine derivatov aril-propionske kisline.
All metabolites of vedaprofen were shown to be less active than the parent compound as determined by a thromboxane B2 formation inhibition assay.
Vsi presnovki vedaprofena so manj učinkoviti kot matična spojina, kar je pokazal preizkus zaviranja nastajanja tromboksana B2.
None known.
Ni smiselno.
Appropriate precautions must be taken for such horses to ensure compliance with competition regulations.
Pri teh konjih je treba paziti, da je zdravljenje v skladu s tekmovalnimi predpisi.
Vedaprofen inhibits the prostaglandin synthesis enzyme system (cyclo-oxygenase enzyme) and thus possesses anti-inflammatory, antipyretic and analgesic properties.
Vedaprofen zavira encim sinteze prostaglandinov (ciklooksigenazo) in deluje protivnetno, antipiretično in analgetično.
Vedaprofen is rapidly absorbed following oral administration.
Vedaprofen se po peroralnem dajanju hitro absorbira.
Quadrisol must not be given with other NSAIDs or glucocorticosteroids.
Quadrisola ne smete dajati hkrati z drugimi nesteroidnimi protivnetnimi zdravili (NSAID) ali glukokortikosteroidi.
Quadrisol 100 mg/ml can be used during pregnancy.
Quadrisol 100 mg/ml se sme dajati v obdobju brejosti.
SPECIAL WARNINGS, IF NECESSARY If side effects occur, treatment should be discontinued.
POSEBNO(A) OPOZORILO(A), ČE JE/SO POTREBNO(A) Če se pojavijo stranski učinki, moramo zdravljenje prekiniti.
EXPIRY DATE EXP: {Month/year}
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA EXP {mesec/leto}
MARKETING AUTHORISATION NUMBER(S) EU/2/97/005/001 (1 x 30 ml)
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/97/005/001 (1 x 30 ml)
QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of Quadrisol oral gel contains:
1 ml peroralnega gela Quadrisol vsebuje:
Shelf-life after first opening of the product: 2 months.
Rok uporabnosti po prvem odpiranju stične ovojnine: 2 meseca
It is advisable to administer the product before feeding.
Zdravilo je priporočljivo dajati pred krmljenjem.
Side effects are reversible.
Neželeni učinki so reverzibilni.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Evropske agencije za zdravila (European Medicines Agency) http://www.ema.europa.eu/
Manufacturers responsible for batch release:
Proizvajalec odgovoren za sproščanje serij:
Studies in the horse have demonstrated potent inhibition of prostaglandin E2 (PG E2) synthesis in exudate and thromboxane B2 synthesis in serum and exudate.
Raziskave pri konjih so pokazale, da močno zavira sintezo prostaglandina E2 (Pg E2) v eksudatu in sintezo tromboksana B2 v serumu in eksudatu.Vsebuje nesimetrični ogljikov atom in je zato racemna zmes (+) enantiomera in (-) enantiomera.
SPECIAL STORAGE CONDITIONS No special precautions for storage.
POSEBNA NAVODILA ZA SHRANJEVANJE Za shranjevanje ni posebnih navodil.
The advised dosage is an initial dose of 2 mg/kg (2.0 ml/100 kg) followed by a maintenance dose of 1 mg/kg (1.0 ml/100 kg) given every 12 hours.
Quadrisol dajemo 2-krat na dan. Priporočeno odmerjanje je začetni odmerek po 2 mg/kg (2,0 ml/100 kg), nato zdravljenje nadaljujemo z vzdrževalnim odmerkom po 1 mg/kg (1,0 ml/100 kg) vsakih 12 ur.
Horses should be monitored for oral lesions during treatment.
Konje je treba med zdravljenjem opazovati, da bi odkrili morebitne poškodbe v ustni votlini.
For full contra-indications, see package leaflet.
Podrobni podatki o kontraindikacijah so v priloženem navodilu.
Typical undesirable effects associated with NSAID use, such as lesions in the alimentary tract, soft faeces, urticaria and lethargy.
Zasledili so značilne neželene učinke nesteroidnih protivnetnih zdravil (NSAID), kot so poškodbe v prebavilih, mehko blato, urtikarija in letargija.
The syringe is fitted with variable dose capability, adjustable in steps of 0.5 ml and graduated to 1 ml.
Brizga ima oznake po 1 ml in je opremljena z nastavkom za različne odmerke, ki jih lahko prilagajamo v stopnjah po 0,5 ml. Na voljo so zloženke z eno brizgo ali tremi brizgami.
Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP.
Rok uporabnosti po prvem odpiranju vsebnika: 2 meseca Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na ovojnini po EXP.
The safety of the veterinary medicinal product has not been established during lactation
Varnost zdravila ni dokazana med laktacijo.
Adjustable dose syringe, containing 30 ml gel 3 adjustable dose syringes, each containing 30 ml gel
3 brizge z nastavljivo velikostjo odmerka s po 30 ml gela
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
4.10 Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi) (če je potrebno) Pojavijo se lahko poškodbe in krvavitve v prebavilih, driska, urtikarija, letargija in zmanjšan tek.
PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic group: non-steroidal anti-inflammatory drug ATCvet code: QM01AE90
Oznaka ATCvet: QM01AE90